The Scientist - Human Ebola vaccine trial begins

Click For Summary
SUMMARY

The Phase I safety trial for a new Ebola vaccine, developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), commenced on November 18. This trial will evaluate the vaccine's DNA component, manufactured by Vical Inc., with 27 subjects participating—21 receiving the vaccine and 6 receiving a placebo. The vaccine employs both naked DNA and an adenoviral vector, with escalating doses of naked plasmid DNA delivered via a needle-less pressure injection method. The trial aims to assess safety over one year, with initial doses of 2 mg, 4 mg, and 8 mg of the vaccine administered monthly.

PREREQUISITES
  • Understanding of vaccine development processes
  • Knowledge of DNA vaccine technology
  • Familiarity with clinical trial phases, particularly Phase I trials
  • Basic comprehension of Ebola virus strains and their epidemiology
NEXT STEPS
  • Research the mechanisms of DNA vaccines and their applications
  • Study the safety protocols and ethical considerations in Phase I clinical trials
  • Explore the epidemiology of Ebola virus and its various strains
  • Investigate the role of adenoviral vectors in vaccine development
USEFUL FOR

This discussion is beneficial for vaccine researchers, clinical trial coordinators, public health officials, and anyone interested in the development and safety assessment of emerging vaccines against infectious diseases like Ebola.

iansmith
Staff Emeritus
Science Advisor
Gold Member
Messages
1,317
Reaction score
2
Phase I safety test of the multimodal vaccine's DNA component will last 1 year | By Jeffrey M Perkel


The leader of the team that designed an Ebola vaccine and tested it in macaque monkeys expects to see no adverse effects in the human trial of the vaccine, which began last Tuesday (November 18). The phase I trial just initiated will test the vaccine's DNA component, manufactured by Vical Inc., a San Diego–based biotech company. The entire vaccine, developed by Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, employs both naked DNA and an adenoviral vector.

The trial will include 27 subjects, 21 of whom will receive the vaccine and six of whom will receive a placebo. At monthly intervals, subjects will receive an escalating dose (2 mg, 4 mg, 8 mg) of naked plasmid DNA—grown in bacteria—encoding Ebola nucleoprotein, the Zaire-subtype glycoprotein, and the Sudan-subtype glycoprotein, in phosphate-buffered saline, delivered via pressure injection into muscle, in a needle-less process. As of last Friday, only two subjects had received injections, according to VRC Director Gary Nabel, who designed and tested the vaccine.

http://www.biomedcentral.com/news/20031124/06
 
Last edited by a moderator:
Biology news on Phys.org
Is Ebola really that much of a killer to warrant a vaccine? Or is it just the fact that it is seen as THE killer virus from the movies which liquifies your organs, rather than something as boring as HIV..
 
Originally posted by Jikx
Is Ebola really that much of a killer to warrant a vaccine? Or is it just the fact that it is seen as THE killer virus from the movies which liquifies your organs, rather than something as boring as HIV..

Yes, Ebola is an hemorrhagic fever but liquification of the organs is rarely seems. Some strains of the virus have an 90% killing rate whereas some other strain have a less than 10% killing rate. Central african countries have sporadic outbreaks killing couple of people.
 

Similar threads

  • · Replies 2 ·
Replies
2
Views
2K
  • · Replies 7 ·
Replies
7
Views
3K
  • · Replies 5 ·
Replies
5
Views
3K